Business Context and Reporting Period
Company: Corcept Therapeutics Incorporated (CORT)
Filing Type: Form 8-K (Current Report)
Date of Report: September 10, 2025
Reporting Period: Event-based report regarding a specific regulatory milestone.
Key Financial Metrics
This filing is a Current Report (Form 8-K) detailing a corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is a regulatory development rather than a financial one:
- Regulatory Acceptance: The U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for relacorilant.
- Indication: The application is for the treatment of patients with platinum-resistant ovarian cancer.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the FDA acceptance but does not include specific forward-looking guidance, financial outlook, or detailed risk factors within the body of this 8-K text.
Unusual Items: None reported in this specific filing text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the FDA review timeline and potential approval dates.
- Confirm the specific clinical data supporting the relacorilant NDA for platinum-resistant ovarian cancer.
- Review subsequent filings for any updates on the FDA's decision or potential regulatory feedback.
- Check the Company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not provide financial data.